GW Research Inc

1. Braintree Laboratories, Inc. $1,153,302 66 payments
2. Vanda Pharmaceuticals Inc. $617,640 71 payments
3. Intercept Pharmaceuticals, Inc. $267,241 51 payments
4. Takeda Pharmaceuticals U.S.A., Inc. $128,403 18 payments
5. Genentech, Inc. $64,528 7 payments
6. Intercept Pharma Europe Ltd. $38,271 7 payments
7. Bausch Health US, LLC $24,200 2 payments
8. Shire North American Group Inc $1,586 3 payments
9. PTC Therapeutics, Inc. $1,125 1 payment

1. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $892,227 22 payments
2. Evaluating the Safety and Efficacy of Tradipitant VS. Placebo in Idiopathic and Diabetic Gastroparesis $350,887 32 payments
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $260,465 38 payments
4. 1011866 $153,113 20 payments
5. Bli4900-302 $112,325 14 payments
6. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $103,780 30 payments
7. A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis $86,044 9 payments
8. Phase II Antifgfr 1 in Nash $64,528 7 payments
9. A PHASE-3, Double-Blind, 29-Week Follow-Up Study to Evaluate the Long-Term Safety of Tegoprazan in Patients with Gastroesophageal Reflux Disease $51,888 13 payments
10. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $48,619 8 payments

1. Other $86,044 9 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.